Skip to main content

Table 1 Dose modifications for patients randomized to Arm A and B, respectively

From: A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

 

Arm A

Arm B

Dose level

Gemcitabine

Gemcitabine

Nab-paclitaxel

0

1000 mg/m2

800 mg/m2

100 mg/m2

-1

800 mg/m2

600 mg/m2

75 mg/m2

-2

600 mg/m2

-

-